Alnylam Pharmace. buy Saftman
Summary
This prediction ended on 08.07.22 with a price of €149.84. With a performance of 2.31%, the BUY prediction by Saftman for Alnylam Pharmace. closed with a slight gain. Saftman has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | -1.761% | -1.761% | -27.386% |
iShares Core DAX® | 1.051% | -1.833% | 12.822% |
iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% |
iShares Nikkei 225® | -1.778% | -8.115% | 16.092% |
iShares S&P 500 | 0.002% | -2.226% | 28.387% |
Comments by Saftman for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.